{"entity":{"id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","aka":[],"tldr":"A phase 2 trial of gemcitabine in triple-negative breast cancer, run by The University of The West Indies, not yet recruiting.","summary":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. is a phase 2, randomised interventional study registered as NCT07528768 by The University of The West Indies, with a registry enrolment figure of 750 participants, started 2027-06-01 and due to reach its primary completion in 2034-06-01. Interventions recorded: Gemcitabine (1000 mg/m^2); Paclitaxel 80 mg/m2 weekly. Conditions listed: Triple Negative Breast Cancer; Metastatic Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Histologically confirmed metastatic triple-negative breast cancer (recent biopsy required)\". Sites: Barbados, Ghana, Jamaica. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07528768","url":"https://clinicaltrials.gov/study/NCT07528768"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07528768","phase":"2","setting":"Triple-Negative Breast Cancer From the West African Source to the Caribbean Diaspora: A Phase II Randomized Clinical Trial With Correlative Molecular and Population-Stratified Analysis in Women of African Ancestry With Metastatic Triple-Negative Breast Cancer.","sponsor":"The University of The West Indies","enrolled":750,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07528768/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}